This isn’t your regular job. Almedia is a place where those who want to push harder can accelerate their careers faster than anywhere else. We’re aiming to become Germany’s second bootstrapped unicorn. Almedia is already Europe’s
About KIRA Our mission is to make money smart, reliable and within reach for everyone. In 2019, we built the first mobile-first, insurance platform, enabling insurance to be accessible online by millions in the region. Today,
Background Sanofi has decided to invest in new, state-of-the-art production facilities for the entire insulin portfolio as part of the InsuLINK program, to ensure a future-oriented, sustainable, and reliable long-term supply for diabetes patients worldwide. Beijing,
Job Description: We believe in bold ideas, diverse perspectives, and the drive to transform knowledge into impact. Here, your curiosity fuels progress, your voice shapes innovation, and your ambition helps redefine what’s possible within science and
This isn’t your regular job. Almedia is a place where those who want to push harder can accelerate their careers faster than anywhere else. We’re aiming to become Germany’s second bootstrapped unicorn. Almedia is already Europe’s
The RoW Central Data Engineering team builds and operates the central data infrastructure backbone for Amazons Rest-of-World (ROW) business operations, serving 5,000+ daily users across 14,000+ dashboards and 70,000+ daily data job runs. We run mission-critical systems
Job title职位名称: M&S Graduate Program-Quality Trainee Location工作地点： Beijing 北京 About Sanofi We’re an R&D-driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. Our deep understanding of the immune system – and innovative
Background Sanofi has decided to invest into new large state-of-the art facilities for the full portfolio for insulin Drug Substances to ensure future oriented, sustainable, reliable and leading-edge long-term supply for world-wide Diabetes patients. The new
Background Sanofi has decided to invest into new large state-of-the art facilities for the full portfolio for insulin Drug Substances to ensure future oriented, sustainable, reliable and leading-edge long-term supply for world-wide Diabetes patients. The new
Background Sanofi has decided to invest into new large state-of-the art facilities for the full portfolio for insulin Drug Substances to ensure future oriented, sustainable, reliable and leading-edge long-term supply for world-wide Diabetes patients. The new